Veltassa files for European approval

25 April 2016

Swiss firm Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency for Veltassa (patiromer) for oral suspension.

VFMCRP, a joint venture of Vifor parent company Galenica and Fresenius Medical Care, is seeking approval of Veltassa for the treatment of hyperkalemia, or elevated blood potassium levels, in the European Union through the EU centralized procedure. Last August, the company gained exclusive marketing right for Veltassa from US biotech firm Relypsa (Nasdaq: RLYP) in worldwide territories except the USA and Japan, where Relypsa retains all commercial rights. Relypsa and VFMCRP are currently collaborating on ongoing development of Veltassa.

Veltassa was approved by the US Food and Drug Administration for the treatment of hyperkalemia on October 21, 2015, becoming the first new medicine in more than 50 years for people with elevated serum potassium.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK